Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bioconjugate pneumococcal vaccine
- Development stage
- Unknown
- Lead developer
- LimmaTech Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bioconjugate pneumococcal vaccine is a candidate investigational vaccine developed by LimmaTech Biologics AG. It is designed to provide protection against bacterial infections caused by *Streptococcus pneumoniae* by eliciting an immune response in healthy adult and elderly subjects. The vaccine is currently undergoing clinical evaluation to assess its safety and immunogenicity.
- Other names
- 10-valent bioconjugate pneumococcal vaccineLimmaTech bioconjugate vaccineStreptococcus pneumoniae bioconjugate vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on bioconjugate pneumococcal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bioconjugate pneumococcal vaccine.